2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
about
The future is today: emerging drugs for the treatment of erectile dysfunctionRandomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215Endothelial dysfunction and erectile dysfunction in the aging man.Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives.Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.Evaluation and treatment of erectile dysfunction in the aging male: a mini-review.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2.Words of wisdom. Re: Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.American Cancer Society prostate cancer survivorship care guidelines.Solid-phase extraction assisted dispersive liquid-liquid microextraction based on solidification of floating organic droplet to determine sildenafil and its analogues in dietary supplements.Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors.Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo.
P2860
Q35186022-88BB2462-EB2A-48C0-ACF2-27B7E297D88BQ36569094-18AF757D-3A45-42F6-9628-9B7DDBAF5F0DQ37650850-14A8D46A-7A7B-4225-BF3D-CD5BFE234EC0Q37686844-C9989468-5EA3-4DA1-A1F3-4F9B309557EBQ37733556-F4213780-99C5-4F21-B035-B41017AFADD8Q37930859-D881080D-697D-44B3-90CF-3FF002BE5FF7Q38107001-288AE3C5-A7A1-466D-AC74-45FED2FFF8D3Q38471773-3C79D336-8D12-40E9-9437-4021B10593A9Q38819020-6DFA9E66-D241-4279-B285-5E559A1787EEQ42869905-E16BA5A6-8F89-4FC7-A6BE-40E70A48C574Q48073617-3A6ED146-871D-44D0-BD86-3BEA0CBC012FQ48271206-96583EFB-C0D4-4353-9737-2CA710A1BBF9Q51686276-E6EA904D-E812-4599-A87F-0F9D73671506Q53105384-1C53387C-59B1-42F5-B358-02854EC8646E
P2860
2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
2009 update on phosphodiestera ...... , and other indications (CME).
@en
2009 update on phosphodiestera ...... , and other indications (CME).
@nl
type
label
2009 update on phosphodiestera ...... , and other indications (CME).
@en
2009 update on phosphodiestera ...... , and other indications (CME).
@nl
prefLabel
2009 update on phosphodiestera ...... , and other indications (CME).
@en
2009 update on phosphodiestera ...... , and other indications (CME).
@nl
P1476
2009 update on phosphodiestera ...... , and other indications (CME).
@en
P2093
Alan W Shindel
P304
1794-808; quiz 1793, 1809-10
P356
10.1111/J.1743-6109.2009.01347.X
P577
2009-07-01T00:00:00Z